Research Papers:

Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse

Ke-Da Yu _, Xin Wang, Chen Yang, Xiao-Hua Zeng and Zhi-Ming Shao

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:26519-26527. https://doi.org/10.18632/oncotarget.4470

Metrics: PDF 1724 views  |   HTML 2034 views  |   ?  


Ke-Da Yu1,*, Xin Wang2,*, Chen Yang3,*, Xiao-Hua Zeng4,*, Zhi-Ming Shao1

1Department of Breast Surgery, Shanghai Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, P.R. China

2Department of Anesthesiology, Shanghai Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, P.R. China

3Department of Medical Oncology, Ruijin Hospital, Shanghai JiaoTong University, Shanghai, P.R. China

4Department of Breast Surgery, Chongqing Cancer Institute/Hospital, Chongqing, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Ke-Da Yu, e-mail: [email protected]

Keywords: chemokine decoy receptor, breast cancer, metastasis, phenotype, genotype

Received: March 22, 2015     Accepted: June 25, 2015     Published: July 06, 2015


Purpose: Chemokines may play vital roles in breast cancer progression and metastasis. The primary members of chemokine decoy receptors (CDR), DARC and D6, are expressed in breast tumors and lymphatic/hematogenous vessels. CDRs sequestrate the pro-malignant chemokines. We hypothesized that breast cancer patients carrying different levels of CDR expression in tumor and/or in host might have differing clinical outcomes.

Methods: This prospective observational study measured both expression and germline genotype of DARC and D6 in 463 primary breast cancer patients enrolled between 2004 and 2006. The endpoint was breast cancer relapse-free survival (RFS).

Results: There was a significant association between the co-expression of CDR (immunohistochemical expression of both DARC and D6) with RFS (hazard ratio [HR] of 0.32, 95% confidence interval [CI] 0.19 to 0.54). Furthermore, the co-genotype of two non-synonymous polymorphisms (with two major alleles of DARC-rs12075 and D6-rs2228468 versus the others) significantly related to relapse. Mechanistically, the variant-alleles of these two polymorphisms significantly decreased by 20–30% of CCL2/CCL5 (CDR ligands) levels relative to their major counterparts. Multivariate analysis highlighted that the co-expression and co-genotype of CDR were independent predictors of RFS, with HR of 0.46 (95% CI 0.27 to 0.80) and 0.56 (95% CI 0.37 to 0.85), respectively. The addition of host CDR genetic information to tumor-based factors (including co-expression of CDR) improved the relapse prediction ability (P = 0.02 of AUC comparison).

Conclusion: The host genotype and tumor phenotype of CDR integrally affect breast cancer relapse. Host-related factors should be considered for individualized prediction of prognosis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4470